Aldeyra Therapeutics (ALDX) Jefferies Global Healthcare Conference 2025 summary

Pipeline overview and recent focus

• Focused on immunology, initially targeting front-of-eye diseases and expanding to broader indications including cancer and autoimmune disorders.

• Lead asset reproxalap is in late-stage development for dry eye disease and allergic conjunctivitis, addressing significant unmet needs for rapid symptom relief.

• Recent activities centered on regulatory submissions and clinical trial data for reproxalap.

Regulatory and clinical development for reproxalap

• Dry eye disease NDA resubmission planned after FDA requested an additional trial due to baseline imbalances in prior data.

• Latest Chamber Trial showed statistically significant results without baseline imbalances; data announced in May.

• Awaiting FDA feedback following a Type A meeting request; NDA resubmission expected pending positive communication.

• Reproxalap would be the first dry eye drug with Chamber Trial data, demonstrating rapid onset of action in minutes.

Commercial and partnership updates

• AbbVie holds an option for co-development and co-commercialization of reproxalap, with a 60/40 P&L split and up to $294 million in potential milestone payments.

• AbbVie remains actively involved in regulatory and development processes; no changes to the agreement reported.